ALK阳性非小细胞肺癌患者中阿来替尼相关体重增加:四项前瞻性临床试验个体患者数据的汇总分析
该汇总分析基于ALEX、J-ALEX、ALUR和ML29453四项前瞻性临床试验的个体患者数据,评估阿来替尼治疗中实际体重增加随时间的变化及其与基线特征的关系。结果显示,任何级别体重增加发生率49%远高于报告的不良事件率5%,18%患者体重增加≥10%;阿来替尼用药时间与体重变化正相关,平均1年增加4.4%。
要点
- 任何级别体重增加实际发生率为49%,远高于报告的不良事件率5%。
- 18%患者体重增加≥10%,中位体重从55.6 kg增至64.1 kg。
- 阿来替尼用药时间与体重变化正相关,平均1年增加4.4%。
核心结论
- 体重增加在临床试验中作为不良事件被低估,任何级别体重增加实际发生率为49%,报告的不良事件率仅为5%。
- 18%的患者实际体重增加≥10%。
- 临床医生应知晓这一不良事件,重视及时识别和监测体重。
- 识别体重增加的预测因素仍具挑战性。
研究设计与样本
- 汇总分析纳入四项前瞻性临床试验(ALEX、J-ALEX、ALUR和ML29453)的个体患者数据。
- 实际体重增加按相对基线的百分比变化计算。
- 采用线性混合模型估计体重随时间的变化及临床特征与体重变化的关联。
- 三项试验(J-ALEX、ALUR和ML29453)有随访体重数据,ALEX缺失。
- 第一年共记录2622次体重测量(N=302)。
主要发现
- 基线时,日本人群中13.6%为体重不足,西方人群中为5.0%。
- 任何级别体重增加实际发生率为49%,报告的不良事件率为5%。
- 18%的患者体重增加≥10%,中位体重从55.6 kg增至64.1 kg。
- 阿来替尼用药时间与体重变化正相关(β = .37;95% CI,0.24至0.51;P < .001),对应1年平均增加4.4%。
- 基线BMI与体重变化无显著关联:J-ALEX(β = -.090 [95% CI,-0.19至0.012];P = .092);ALUR/ML29453(β = -.016 [95% CI,-0.077至0.044];P = .59)。
关键数值与推荐
- 任何级别体重增加:实际发生率49% vs 报告的不良事件率5%。
- 体重增加≥10%:18%的患者,中位体重从55.6 kg增至64.1 kg。
- 用药时间与体重变化:β = .37(95% CI,0.24至0.51;P < .001),1年平均增加4.4%。
- 基线BMI与体重变化:J-ALEX β = -.090(95% CI,-0.19至0.012;P = .092);ALUR/ML29453 β = -.016(95% CI,-0.077至0.044;P = .59)。
- 基线白蛋白与体重变化:ALUR/ML29453 β = .084(95% CI,0.027至0.14;P = .0045)。
临床怎么用
- 临床医生应知晓阿来替尼相关体重增加这一不良事件,重视及时识别和监测体重。
- 原文未据此给出其他推荐。
局限性
- ALEX试验的随访体重数据缺失。
- 识别体重增加的预测因素仍具挑战性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Weight gain is a known adverse event (AE) of alectinib. This study evaluates the progression of actual weight gain over time and explores its association with baseline characteristics. METHODS: A pooled analysis of individual patient data from four clinical trials (ALEX, J-ALEX, ALUR, and ML29453) was conducted. Actual weight gain was calculated as the percent change from baseline. A linear mixed model estimated weight change over time and associations between clinical characteristics and weight change. RESULTS: Follow-up weights were available for three trials (J-ALEX, ALUR, and ML29453) and missing for ALEX. In total, 2,622 weights were recorded in the first year (N = 302). At baseline, 13.6% of the Japanese population were underweight and 5.0% in the Western population. Actual weight gain of any grade was substantially higher than reported AE rates (49% v 5%), with 18% experiencing ≥10% weight gain (from median 55.6 kg to 64.1 kg). Time on alectinib was positively associated with weight change (β = .37; 95% CI, 0.24 to 0.51; P < .001), corresponding to an average increase of 4.4% over 1 year. Baseline BMI was not associated with weight change in J-ALEX (β = -.090 [95% CI, -0.19 to 0.012]; P = .092) and ALUR/ML29453 (β = -.016 [95% CI, -0.077 to 0.044]; P = .59). Baseline albumin was positively associated with weight change in ALUR/ML29453 (β = .084 [95% CI, 0.027 to 0.14]; P = .0045), although not considered a clinically meaningful predictor. CONCLUSION: Weight gain is under-reported as AE in trials. Actual weights showed ≥10% weight gain in 18% of patients. Clinicians should be aware of this AE, emphasizing the importance of timely identification and monitoring weight. Identifying predictors for weight gain remains challenging.
引用
- Sikkema BJ, Baart SJ, Paats MS, et al. Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials. J Clin Oncol. 2024. PMID: 39661917. doi:10.1200/JCO-24-01579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。